Straits Times Index
3,266.05 +1.52 (+0.05%) Nikkei
38,321.87 +119.50 (+0.31%) Hang Seng
18,538.57 +224.71 (+1.23%) FTSE 100
8,354.05 +40.38 (+0.49%) Bitcoin USD
61,526.89 -1,081.79 (-1.73%) CMC Crypto 200
1,310.72 +16.05 (+1.24%)
Aileron Therapeutics, Inc. (ALRN)
| Previous close | 3.6900 |
| Open | 3.6500 |
| Bid | 3.5700 x 100 |
| Ask | 3.7800 x 100 |
| Day's range | 3.5600 - 3.6800 |
| 52-week range | 1.0100 - 7.4200 |
| Volume | |
| Avg. volume | 90,019 |
| Market cap | 77.168M |
| Beta (5Y monthly) | 2.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.4200 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.00 |
ZacksDown -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
GlobeNewswireAileron Therapeutics to Present at Two Upcoming Investor Conferences
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Citizens JMP Life Sciences ConferenceDate: Monday, May 13, 2024Time: 12:00 p.m. EDTFormat: C
- GlobeNewswire
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offeringAUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the closing of its pr
